Therapix's THX-101 meets in Phase IIa data for Tourette's syndrome

Therapix Biosciences Ltd. (NASDAQ:TRPX) reported top-line data from a single-arm, open-label Phase IIa trial in 16 medication-refractory patients with Tourette's syndrome showing that once-daily oral THX-110 (THX-TS01) met the primary endpoint of reducing tic symptoms as measured by mean Yale Global Tic Severity Scale (YGTSS) total tic score at week 12 compared with baseline (30.5 vs. 38.4 points, p=0.002). Additionally, six patients achieved a reduction in YGTSS total tic score of >25%. The trial was sponsored by Yale University. Data will be presented at the European Society for the Study of Tourette syndrome meeting in Copenhagen in June.

By 3Q18, Therapix plans to start a Phase IIb trial of THX-110 in 60 patients with Tourette's syndrome. THX-110 is a combination of dronabinol, the psychoactive molecule in the cannabis plant, and palmitoylethanolamide (PEA), an endogenous fatty acid amide...